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Amaç: Helikobakter pilori ile oluﬂan infeksiyonun sistemik inflamasyona ve vasküler endotelyal hasara yol açabilece¤i düﬂünül-
mektedir. Bu nedenle, idrarla at›lan albumin düzeyindeki art›ﬂ›n bu infeksiyon sonucu meydana gelen glomerular hasara ba¤l› ola-
bilece¤i varsay›labilir. Bu çal›ﬂmada, Helikobakter pilori infeksiyonu ile mikroalbuminüri aras›ndaki iliﬂki bu hipoteze dayan›la-
rak incelendi. Yöntem: Tip 2 diyabetes mellitus tan›l› 93 hasta çal›ﬂmaya dahil edildi. Bu hastalar Helikobakter pilori infeksiyo-
nu varl›¤›na gore; infekte olanlar (Grup 1) ve olmayanlar (Grup 2) ﬂeklinde iki gruba ayr›ld›. Tüm hastalarda idrarla at›lan albu-
min miktar› ile çal›ﬂman›n di¤er de¤iﬂkenleri karﬂ›laﬂt›r›ld›. Bulgular: Diyabetik 93 hastan›n 53’ünde (%56.98) Helikobakter pi-
lori infeksiyonu saptand›. ‹nfekte olan diyabetiklerde, infekte olmayanlara gore mikroalbuminüri düzeyinin anlaml› olarak daha
yüksek oldu¤u saptand› (s›ras›yla, 186.7±24.2 mg/24h ve 131.2±11.6 mg/24h, p=0.012). Benzer ﬂekilde infekte diyabetiklerde inf-
lamasyon göstergelerinin infekte olmayanlara oranla anlaml› olarak daha yüksek oldu¤u belirlendi (p<0.05). Diyabetik hastalar-
da Helikobakter pilori infeksiyonu ile mikroalbuminüri aras›ndaki iliﬂkinin çal›ﬂman›n di¤er de¤iﬂkenlerinden ba¤›ms›z oldu¤u
saptand›. Sonuç: Helikobakter pilori infeksiyonu, oluﬂturdu¤u sistemik inflamatuvar yan›t nedeniyle, diyabetik nefropatinin geliﬂ-
mesinde veya ilerlemesinde önemli bir rol oynayabilir. Bu çal›ﬂma, diyabetik mikroalbuminüri ile Helikobakter pilori infeksiyonu
aras›ndaki iliﬂkiyi göstermede, hasta say›s›n›n azl›¤› nedeniyle yetersizdir. Bu nedenle, daha fazla say›da hastay› kapsayan klinik
ve moleküler çal›ﬂmalarla desteklenmesi gerekmektedir.
Anahtar kelimeler: Helikobakter pilori, mikroalbuminüri, diabetes mellitus, sistemik inflamasyon
Background/aims: As default, Helicobacter pylori infection may cause systemic inflammation and vascular endothelial damage.
Therefore, it can be assumed that the glomerular damage as a result may lead to an increase in urinary albumin excretion. In this
study, this hypothesis was set, and the relationship between Helicobacter pylori infection and microalbuminuria was examined.
Methods: Ninety-three patients with type 2 diabetes were included in the study. These patients were divided into two groups as He-
licobacter pylori infection-positive (Group 1) or -negative (Group 2). In all infected and non-infected patients, urinary albumin ex-
cretion and other parameters were compared. Results: The presence of Helicobacter pylori infection was detected in 53 of 93 diabe-
tic patients (56.98%). Diabetic patients infected by Helicobacter pylori (Group 1; 186.7±24.2 mg/24 h) showed significantly higher
microalbuminuria than non-infected patients (Group 2; 131.2±11.6 mg/24 h) (p=0.012). Diabetics infected with Helicobacter pylo-
ri had significantly higher inflammation marker levels than non-infected patients (p<0.05). It has been concluded that the relation
between microalbuminuria level and Helicobacter pylori infection in diabetics is independent from other study variables. Conclu-
sions: Helicobacter pylori infection, because of the systemic inflammatory response, may play an important role in the progression
of diabetic nephropathy or its development. In this study, demonstrating the relationship between Helicobacter pylori infection with
diabetic microalbuminuria, due to the small number of patients, is inadequate. Therefore, clinical and molecular studies involving
more patients should be supported.
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ORIGINAL ARTICLE
Tip 2 diyabetik hastalarda Helikobakter pilori infeksiyonu ile 
mikroalbuminüri aras›ndaki iliﬂki
INTRODUCTION
Microalbuminuria (Malb) is a confirmed marker of
diabetic nephropathy (1). The appearance of albu-
min in urine is thought to be the consequence of
generalized endothelial damage along the vascu-
lar area including the glomerulus (1). Various in-
fectious diseases may be listed among the etiologic
factors related with this vascular endothelial da-
mage and consequently developing atherosclero-
sis. Hepatitis B and C virus, chlamydia, Epstein-
Barr virus, cytomegalovirus, and as shown in re-
cent studies, Helicobacter pylori (H. pylori), are
these microorganisms (2-5). H. pylori, particularly
notable in developing countries, and affecting ap-
proximately 50% of the world population, is a
gram-negative, spiral and microaerophilic bacteri-
um (3,5). Its inflammatory response models have
not been elucidated yet (3).
We performed a cross-sectional case control study
to investigate a possible association between Malb
and infection by H. pylori in a population of type 2
diabetic patients.
MATERIALS AND METHODS
Patients
The subjects of the present study were selected
from patients attending the outpatient depart-
ment during the period April 2004 to August 2004
in the first center and September 2005 to Novem-
ber 2006 in the second center. A population of 93
diabetic outpatients was analyzed through a revi-
ew of clinical records and personal interview. Sub-
jects diagnosed as suffering from type 2 diabetes
mellitus according to the report of the Expert
Committee for the Diagnosis and Classification of
Diabetes Mellitus were included in the study (6).
Diabetes mellitus was defined as diabetes treated
by diet alone or by diet combined with oral hypogl-
ycemic agents or as treatment with insulin in a ca-
se of diabetes onset after the age of 40 years. Inc-
lusion criteria were the following parameters: age
of onset >40 years, duration of diabetes <4 years,
absence of proteinuria with the dipstick test, se-
rum creatinine <1.5 mg/dl, serum triglyceride le-
vel <400 mg/dl, negative urine culture, and the ab-
sence of the other exclusion criteria.
The subjects were divided into two groups accor-
ding to H. pylori infection as Group 1 (H. pylori-
positive) and Group 2 (H. pylori-negative). 
Ethics
The protocol of this study conformed to the local
ethical guidelines and informed written consent
was obtained from each participant. The study be-
gan following approval of the Academic Ethics
Committee on March 12, 2004 in first center and
on September 19, 2005 in second center. 
Exclusion Criteria Used in the Study 
Exclusion criteria were as follows: (i) those previo-
usly diagnosed to have H. pylori infection or those
who had undergone or were currently undergoing
H. pylori eradication, (ii) those receiving anti-ulcer
treatment in the last three months and still recei-
ving proton-pump inhibitors (PPI) or H2 receptor
blockers, (iii) diabetic patients with poor glucose
regulation diagnosed previously and detected in
laboratory parameters as having nephropathy, re-
tinopathy, neuropathy, or ischemic cardiovascular
disease, and diabetics having >120 mmHg systolic
blood pressure and >85 mmHg diastolic blood
pressure, (iv) those with vascular or inflammatory
disease, those obliged to continue antibiotic treat-
ment for various reasons, and those suspected for
or diagnosed as rheumatoid or immunological di-
sease, (v) diabetics with periodontal disease diag-
nosed by a dentist and requiring intensive treat-
ment and those with poor oral hygiene, (vi) smo-
kers, (vii) those not providing consent for the
study, and (viii) those with poor socioeconomic le-
vel unable to return for follow-ups regularly.
Parameters and Measurement Methods Used
Throughout the Study 
Demographic and clinical parameters of the study
were age (years), gender (male or female), anti-di-
abetic treatment (diet or oral anti-diabetics or in-
sulin), body mass index (BMI, kg/m2), duration of
diabetes (years), systolic blood pressure (mmHg),
and diastolic blood pressure (mmHg). Laboratory
parameters were total cholesterol (mg/dl), blood
glucose (mg/dl), triglyceride (mg/dl), high-density
lipoprotein-cholesterol (HDL-C, mg/dl), low-den-
sity lipoprotein-cholesterol (LDL-C, mg/dl),
glycosylated hemoglobin (HbA1c, %), leukocyte
(103/mm3) and platelet  (103/mm3)  counts, eryt-
hrocyte sedimentation rate (ESR, mm/hour), C-re-
active protein (CRP, mg/dl), fibrinogen (mg/dl), li-
poprotein (a) (LPa, mg/dl), and Malb levels (mg/24
hours). The presence of H. pylori infection was al-
so assessed. 
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Outcome Data and Assays
Body mass index (BMI) was calculated by using
the Quetelet index (weight/length2=kg/m2) (7). Blo-
od pressure was calculated based on Korotkoff
Phase-I and Phase-V sounds through both arms
with a mercury sphygmomanometer after 10 mi-
nutes rest while sitting. A systolic pressure of over
120 mmHg and a diastolic pressure of over 85
mmHg were accepted as hypertension (7). Plasma
glucose (hexokinase method), total cholesterol
(enzymatic method), triglyceride (enzymatic met-
hod without glycerol blocking), and HDL-C (dex-
tran sulfate- MgCl2 precipitation) were measured
on a Hitachi 911 automated analyzer using rea-
gent kits supplied by the manufacturer of the
analyzer. LDL-C was calculated by the Friedewald
equation (7). HbA1c was measured by an automa-
ted ion-exchange chromatographic method, and
the reference range was 5.1-6.4%. The CRP level
was determined by the immunoturbidimetric met-
hod, and a Cobas Integra auto-analyzer was used
for the measurement. Measurement of fibrinogen
was realized in citrated plasma on a Behring Nep-
helometer Bien 100 instrument (Dade Behring Di-
agnostic, Liederbach, Germany). This method de-
veloped to measure fibrinogen (mg/dl) in plasma
depends on immune complex formation of plasma
factors by specific antibodies through an immu-
nochemical reaction, radiation of light beam pas-
sing through these complexes, and proportional
change of radiated light with the protein being
measured. Serum LPa level (mg/dl) was measured
using the enzyme immunoassay kit (Boehringer-
Mannheim Biochemica). 
The presence of cerebrovascular disease was docu-
mented with a central nervous system computed
tomography and consultation with a neurologist.
Peripheral vascular disease was clinically defined
by the presence of intermittent claudication, ab-
sent or weakened peripheral pulses, or both. Reti-
nopathy was documented by standard fundus exa-
mination. Clinical neuropathy was defined by an
abnormal examination, consistent with the pre-
sence of peripheral sensorimotor neuropathy. Co-
ronary heart disease was clinically assessed and
supported with electrocardiographic findings. Ad-
vanced nephropathy was defined by the presence
of urinary albumin excretion ≥300 mg per 24 ho-
urs and a rate of creatinine clearance <70 ml/min.
Determination of Malb
Urinary albumin excretion was measured by nep-
helometric test for the measurement of Malb in
urine. Three consequent Malb measurements we-
re performed in three months and those with 24-
hour urinary albumin excretion between 30-300
mg on at least two measurements were accepted
as micro-albuminuric (1,2). Since heavy exercise,
excessive protein ingestion, fluid overlaod, and
urinary tract infections increase the urinary pro-
tein excretion, these conditions were discarded du-
ring Malb measurements. 
Assessment of Helicobacter pylori Infection
Three endoscopic biopsy samples were obtained
from the antral mucosa of each patient. Two bi-
opsy samples were placed into 10% formol soluti-
on and dyed by Giemsa and hematoxylin-eosin,
and investigated for H. pylori. Another tissue
sample was used for rapid urease test, also known
as the Campylobacter-like organism (CLO) test.
The CLO test was monitored for color change up to
24 hours after the addition of the gastric tissue. A
pink coloration was interpreted as positive. Histo-
logy-positive patients were those with curved or-
ganisms seen in hematoxylin and eosin-stained
sections under the microscope. When either the
histopathology or the urease tests were positive,
the H. pylori infection was confirmed (8). H. pylo-
ri infection was shown in all patients with histo-
pathological results. Urease test was negative in
only 8 patients. Since the diagnosis of H. pylori
has a sensitivity of 93–99% and specificity of 95-
99%, the diagnosis was established by the histo-
pathological method accepted as the “gold stan-
dard” (8). Due to financial difficulties, specific
strain identification directed towards H. pylori co-
uld not be performed. The endoscopic findings ob-
tained from all patients were recorded. The relati-
onships between these findings and study variab-
les were investigated and it was attempted to de-
termine any effect(s) on inflammation indicators. 
Statistical Evaluation
All data were expressed as mean±SD or median
range as appropriate. The distribution of variables
was analyzed with the Kolmogorov-Smirnov test.
Quantitative variables with normal distribution
were analyzed with a two-tailed, independent Stu-
dent’s t test. Nonparametric variables were analy-
zed with the Mann-Whitney U test. However, qu-
alitative parameters were analyzed with the chi-
square test and Fisher’s test. Kruskal-Wallis test
was used while making comparisons between en-
doscopic findings and study variables. The relati-
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onship between urine albumin excretion and other
study variables was made by using Spearman cor-
relation coefficient and logistic regression analy-
sis. Results were evaluated in 95% confidence in-
terval, at p<0.05 significance level. All analyses
were performed using the Statistical Package for
the Social Sciences (SPSS) version 11.
RESULTS
The demographic, clinical and laboratory charac-
teristics of patients in this study (Groups 1 and 2)
are displayed in Table 1.
The presence of H. pylori infection was detected in
53 of 93 diabetic patients (56.98%). Diabetic pati-
ents infected by H. pylori (Group 1; 186.7±24.2
mg/24 h) showed significantly higher Malb than
non-infected patients (Group 2; 131.2±11.6 mg/24
h) (p=0.012) (Table 2). Infected diabetics with H.
pylori had significantly higher leukocyte and pla-
telet counts, ESR, serum CRP, fibrinogen, and
LPa levels than non-infected diabetics (p=0.011,
p=0.041, p=0.024, p=0.019, p=0.027, respectively)
(Table 2). 
The endoscopic findings detected for all patients
participating in the study are given in Table 3. No
relationship between endoscopic findings and uri-
ne albumin excretion or other study variables was
detected.  
It has been concluded that the relation between
Malb level and H. pylori infection in diabetics is
independent from other study variables (sex, di-
abetes duration, HbA1c, blood pressure, lipid pro-
file, diabetes treatment) (p=0.025; OR=3.32, CI
95% 1.16- 9.50).
DISCUSSION
The Malb levels were higher in patients with H.
pylori infection than in those without H. pylori in-
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Parameters Group 1 Group 2 P*
(infected with H. pylori) (non-infected with H. pylori)
Patients (n) 53 40 -
Age (year) 58±11 52±8 -
Male/female (n) 28/ 25 21/19 -
Blood glucose level (mg/dl) 126.4±8.3 115.6±5.1 >0.05
HbA1c (%) 6.9±1.2 6.1±1.4 0.055¥
Total cholesterol level (mg/dl) 192.2±13.1 187.4±10.2 >0.05
Triglycerides level (mg/dl) 199.4±13.1 195.6±11.4 >0.05
HDL-cholesterol level (mg/dl) 28.5±6.4 27.2±4.1 >0.05
LDL-cholesterol level (mg/dl) 121.7±7.1 126.3±5.4 >0.05
Body mass index (kg/m2) 29.1±2.7 27.1±2.3 >0.05
Systolic blood pressure (mmHg) 104.3±11.4 105.2±8.2 0.056¥
Diastolic blood pressure (mmHg) 88.4±6.2 86.2±4.3 >0.05
Oral anti-diabetics/insulin 28/ 25 16/ 24 >0.05
Diabetic duration (year) 2.9±0.8 2.8±0.5 >0.05
* A two tailed p value of <0.05 was considered statistically significant, ¥not statistically significant for each group.
Table 1. The demographic, clinical and laboratory characteristics of patients in the infected (Group 1) and non-
infected (Group 2) patients
Parameters Group 1 Group 2 P*
(infected with H. pylori) (non-infected with H. pylori)
Urine protein excretion (mg/24 h) 186.7±24.2 131.2±11.6 P<0.05
Fibrinogen level (mg/dl) 532.2±46.4 498.5±23.3 P<0.05
C-reactive protein (mg/dl) 32.4±9.7 27.5±9.3 P<0.05
Lipoprotein-a level (mg/dl) 39.1±8.2 31.3±5.2 P<0.05
Leukocyte count (103/mm3) 12.1±1.9 9.8±2.4 P<0.05
Platelet count (103/mm3) 512.45±98. 4 467. 51±78.6 P<0.05
* A two tailed p value of <0.05 was considered statistically significant.
Table 2. The inflammation markers and urine protein excretion levels of patients in the infected (Group 1) and
non-infected (Group 2) patients
fection. This study is the first to describe any rela-
tionship with H. pylori in a diabetic population
with Malb. The prevalence of H. pylori infection
has been reported to range between 30%-80% in
diabetic patients (9-18). In this recent study of our
institute, the prevalence of H. pylori infection in
diabetics was found to be 56.98%, and this rate
was concordant with the values observed in other
studies.
Malb has been shown to be consistently associated
with endothelial low-grade inflammation (19).
Ross (20) has proposed that dysfunction of the vas-
cular endothelium and chronic systemic low-grade
inflammation are the key features in the pathoph-
ysiology of atherothrombosis and Malb. Although
a certain value has not been determined about the
frequency, it has been demonstrated that persis-
tent systemic inflammatory response related with
H. pylori increases the vascular injury in diabetics
and predisposes them to pulmonary, cardiovascu-
lar and cerebral diseases (9,10,21). H. pylori infec-
tion has been hypothesized to contribute to a
strong inflammatory response, atherogenesis and
plaque instability (22). It is thought that pro-inf-
lammatory factors are produced at excessive amo-
unts in this infection, and cross-reaction between
the released mediators and host antigens causes
gastric injury and extra-digestive manifestations
(21). Studies have demonstrated a significant rela-
tion between LPa, HDL-C, oxidant lipids, LDL-C,
thrombotic activation-related anti-thrombin (AT)-
III, von-Willebrand factor, interleukin-1, tumor
necrosis factor, and interleukin-6 and H. pylori in-
fection (23-25). Unfortunately, certain evidence
has not been presented on the predicted changes
in renal microvascular structure of H. pylori, ac-
cepted to have a notable relation with atheroscle-
rosis and particularly with coronary artery disea-
se. In the present study, inflammation markers
(CRP and fibrinogen levels, ESR and leukocyte co-
unt) and thrombotic activation markers (LPa le-
vel) were found to be significantly increased in in-
fected diabetic patients. Nevertheless, the micro-
albuminuric process related with endothelial
dysfunction that forms the first step of systemic
vascular response and vascular injury, particu-
larly in diabetics, and the relationship with H.
pylori infection have not been sufficiently empha-
sized in recent studies. In a limited number of stu-
dies, no definite result regarding the relation bet-
ween diabetic nephropathy and H. pylori infection
was obtained. In a study by Pietroiusti et al. (21),
infections produced by cytotoxin-associated gene-
A (cagA), thought to cause cross-reaction with en-
dothelial antigens carrying H. pylori strains, were
shown to be related with diabetic Malb.
This present study is inadequate for drawing a
conclusion regarding a definite relationship bet-
ween H. pylori infection and diabetic Malb, prima-
rily because of the small number of patients.
In conclusion, further studies with large patients’
series and involving many inflammatory markers
and antigenic molecules may put forth a discussi-
on on another absolute indication of H. pylori era-
dication. 
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Endoscopic findings Group 1 Group 2 P*
(infected with H. pylori) (non-infected with H. pylori)
Patients (n) 53 40 -
Normal endoscopy n, (%) 30 (56.61%) 24 (60%) >0.05
Abnormal endoscopy n, (%) 23 (43.39%) 16 (40%) 0.057¥
Pangastritis n, (%£) 3 (13.04%) 2 (12.5%) >0.05
Atrophic gastritis  n, (%£) 2 (8.69%) 1 (6.25%) >0.05
Antral gastritis n, (%£) 6 (26.08%) 3 (18.75%) >0.05
Duodenitis n, (%£) 4 (17.39%) 3 (18.75%) >0.05
Duodenal ulcer n, (%£) 1 (4.34%) 1 (6.25%) >0.05
Gastric ulcer n, (%£) 1 (4.34%) 1 (6.25%) >0.05
Esophagitis n, (%£) 6 (26.08%) 5 (31.25%) >0.05
* A two-tailed p value of <0.05 was considered statistically significant, ¥not statistically significant for each group; £shows the ratio of patients
with an abnormal endoscopy.
Table 3. Endoscopic findings for all patients
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